FILE PHOTO: Chinese vaccine maker CanSino Biologics' sign is pictured on its building in Tianjin, China November 20, 2018. REUTERS/Stringer
DUBAI (Reuters) - Saudi Arabia will soon begin Phase III clinical trials on around 5,000 people for a COVID-19 vaccine developed by China's CanSino Biologics Inc <6185.HK>, a Saudi health ministry spokesman said on Sunday.
Last month, CanSino's co-founder said the company was in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of the vaccine candidate, Ad5-nCOV. [nL3N2EI032]
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
